Arecor advancing today’s therapies to enable healthier lives

Arecor is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. Arecor’s innovative proprietary formulation technology platform Arestat(TM) enables conversion of sub-optimal products to superior product formats to improve patient outcomes.

Arecor Therapeutics PLC (AIM:AREC) announced that the European Patent Office has upheld its patent on polysaccharide vaccines after dismissing an opposition appeal by GlaxoSmithKline PLC (LSE:GSK).

The biopharma group said its European patent EP2457590 protects novel compositions of polysaccharide vaccines, such as those used to prevent meningitis or pneumonia. Polysaccharide vaccines can degrade over time, leading to gradual loss of potency, but Arecor said its novel compositions, protected by the patent, prevent degradation and can help develop improved vaccines.

At an oral hearing on 1, the board of appeal at the European Patent Office considered an appeal filed by GSK in response to an earlier ruling in Arecor’s favour and decided to dismiss the appeal, upholding the patent as granted.

Commenting on the ruling, Arecor’s chief scientific officer Dr Jan Jezek said: “We are delighted about the successful outcome of this appeal. Having developed a highly innovative formulation technology, Arecor has firmly established itself as a world leader in the formulation of superior therapeutic and vaccine products.

Arecor Therapeutics PLC (AIM:AREC) said it is well-placed to advance its pipeline following the GBP20mln capital raise on its IPO.

The pharma group is planning further clinical trials for its lead products, including the expected completion of a US Phase I clinical trial for ultra-rapid acting insulin AT247.

Arecor Therapeutics PLC (AIM:AREC) said its ultra-concentrated, rapid-acting insulin formulation hit its primary goal in a phase I clinical trial.

AT278 was pitted against a product called NovoRapid in the early-stage evaluation, which assessed pharmacokinetics (the time taken for the drug to be absorbed and distributed), pharmacodynamics (the treatment’s effects) and safety.

() is going from strength to strength ahead of launching its insulin products.

The pharma group, which floated London’s junior market in June, has developed Arestat, a technology platform that allows drugs to be delivered more easily into patients’ bodies.

Arecor Therapeutics’ (LON:AREC) CEO Sarah Howell joins Proactive London to talks through their latest results and pipeline, including the expected completion of a US Phase I clinical trial for ultra-rapid acting insulin AT247.

Howell explains how their rapid insulin has shown significant promise in an early-stage clinical trial with results from the Phase I clinical trial for AT278, an ultra-concentrated ultra-rapid acting insulin, showing better results than the widely marketed NovoRapid.

In the six months ended 30 June, revenue came in at GBP500,000 from GBP800,000 the year before, with loss after tax of GBP3mln from GBP1mln in 2020.